n "> (Reuters) - J & J (JNJ.)"(N) is pursued by a company called oral International Cancer Prevention who has supported major drug "Edit" with a contract of sale related to the distribution of a product of oral cancer prevention to protect sales of its popular mouthwashes, Listerine, according to court documents.
The complaint accuses J & J on three counts: fraud, tortuous interference with contract and civil conspiracy. It aims to at least 60 million dollars in damages and at least $ 10 million in damages punitive on each of the three counts.
The trial is on a contract that oral Cancer Prevention signed in February 2010 with the former J & J unit, OraPharma Inc., whereby OraPharma distributed exclusively oral CDx brush Test of OPIC, which identifies precancerous cells in the mouth.
The complaint said that j & J is concerned a study published in Australia connecting mouthwash with a cancer high alcohol content, adding that J & J did not "give faith to the link between Listerine and cancer of the mouth" by selling his mouthwash and the OralCDx.
"Johnson & Johnson induced by OraPharma break the contract of sale to suppress sales of deny the public a product of oral cancer prevention proven life-saving", said the complaint filed on July 6.
The prosecution was filed before the Federal Court in Trenton, New Jersey.
"The company believes that we have engaged in proper business practices and we look forward to the opportunity to settle this matter through the legal system", J & J Bill Price spokesman told Reuters.
OraPharma could not be reached immediately for comment.
The case is oral Cancer Prevention v. Johnson & Johnson and Johnson & Johnson Consumer SOC, 11-cv-03878, the United States District Court, District of New Jersey (Trenton).
(Reporting by Mihir Dalal in Bangalore; editing by Carol Bishopric)
No comments:
Post a Comment